RCS - Synairgen plc - Appointment of Chief Medical Officer

SynairgenAnnouncement

03/10/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231003:nRSC4237Oa&default-theme=true

RNS Number : 4237O  Synairgen plc  03 October 2023

Synairgen plc

('Synairgen' or the 'Company')

Synairgen appoints Dr Marcin Mankowski as Chief Medical Officer

·      New full-time role created as Synairgen progresses clinical
development strategy

Southampton, UK - 3 October 2023: Synairgen plc (LSE: SNG), the respiratory
company developing SNG001, an investigational formulation for inhalation
containing the immunomodulatory broad-spectrum antiviral protein interferon
beta, today announces the appointment of Dr Marcin Mankowski as Chief Medical
Officer (CMO), effective immediately.

Marcin is a seasoned pharmaceutical physician and drug developer with more
than 27 years of pharmaceutical industry experience and a strong background in
infectious diseases and respiratory medicine. Marcin joins Synairgen on a
full-time basis having worked with the Company as acting CMO and a clinical
trials consultant since 2018.

Prior to joining Synairgen, Marcin was Co-Founder and Chief Executive Officer
at tranScrip Ltd, a leading contract drug development business, where he
played an integral strategic role in both driving investment as well as
leading a vast range of projects across all stages of drug development and
multiple therapy areas.

Commenting on Marcin's full time appointment today, Richard Marsden, CEO of
Synairgen, said: "I am delighted that Marcin will be joining us as CMO in a
full time capacity.  Since 2018, he has been supporting and guiding us on our
clinical trials and his appointment today underlines his belief in our drug.
Marcin's in-depth knowledge of the Company and SNG001 as well as his strong
track record in leading the strategy, design and implementation of global
clinical development programmes, will be invaluable to us as we prepare to
enter further clinical trials of SNG001."

Dr Marcin Mankowski, newly appointed CMO of Synairgen, added: "I look forward
to be working more closely with and supporting the team at Synairgen as it
progresses towards more targeted clinical trials of SNG001 to maximise the
benefits of treatment and address the high unmet medical need."

 

For further enquiries, please contact:

 

Synairgen plc

Media@synairgen.com (mailto:Media@synairgen.com)

Tel: + 44 (0) 23 8051 2800

 

ICR Consilium (Financial Media and Investor Relations)

Mary-Jane Elliott, Namrata Taak, Lucy Featherstone

Synairgen@consilium-comms.com (mailto:Synairgen@consilium-comms.com)

Tel: +44 (0) 20 3709 5700

 

 

Notes for Editors

 

Synairgen is a UK-based respiratory company focused on drug discovery and the
development of SNG001 (inhaled interferon beta) as potentially the first
host-targeted, broad-spectrum antiviral treatment delivered directly into the
lungs for severe viral lung infections.

 

Millions of people globally are hospitalised every year due to viral lung
infections and there are currently no approved antiviral therapies for the
majority of these patients. Synairgen is developing SNG001 to address this
need.

Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen,
please see www.synairgen.com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEASEAEFLDFFA